Hadasit Bio-Holdings

Press Releases

Hadasit Bio-Holdings to Participate in Hadassah Centennial Convention

Oct. 16, 2012

Hadasit Bio-Holdings Ltd. (OTC: HADSY, TASE: HDST) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel’s foremost medical research center, announced today that Ophir Shahaf, the Company’s Chief Executive Officer, will be a member of the Hadassah Centennial Convention’s Business Session panel on Thursday, October 18th in Jerusalem.

As part of the panel, Mr. Shahaf will lead discussions and field questions from over 400 Hadassah Associates. Topics covered will range from the innovative model used by Hadasit Bio-Holdings to commercialize and finance biotechnology innovation stemming from a leading research center, to recent developments in some of the promising companies that comprise the Hadasit Bio-Holdings portfolio, to current trends in the Biotechnology industry, and much more. Mr. Shahaf’s extensive experience in the biotech industry and as the CEO of Hadasit Bio-Holdings for over five years will provide invaluable insight for those in attendance.

The Company is also pleased to announce that its stock now has Blue Sky exemption in over 30 states. Obtaining Blue Sky exemption allows financial advisors and brokers to solicit the stock to their clients.

“I am very excited to have the opportunity to speak with so many interested parties at the Centennial Convention. This will be a great event where people can learn a lot about Hadasit Bio-Holdings and the amazing science we are producing,” stated Mr. Shahaf. “Additionally, now that we are Blue Skied in various states across the U.S., it will allow for increased visibility and liquidity in the trading of our ADR, and enable a wider audience to participate in these highly promising companies, all ‘born and bred’ within Hadassah - a leader in medical and scientific innovation.”

 
 

Press Releases Archive